Evidence map›Paper›PMID 30518672›Full record

ArticleMolecular cancer therapeutics2019

Cooperative Effect of Oncogenic

Shuying Liu, Shunqiang Li, Bailiang Wang, Wenbin Liu, Mihai Gagea, Huiqin Chen, Joohyuk Sohn, Napa Parinyanitikul, Tina Primeau, Kim-Anh Do and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Current oncology (Toronto, Ont.) · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Shuying LiuDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. dtripathy@mdanderson.org sliu@mdanderson.org.
Shunqiang LiSection of Breast Oncology, Department of Internal Medicine, Washington University in St. Louis, St. Louis, Missouri.
Bailiang WangDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Wenbin LiuDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mihai GageaDepartment of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Huiqin ChenDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Joohyuk SohnDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Napa ParinyanitikulDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-3701-5663
Tina PrimeauSection of Breast Oncology, Department of Internal Medicine, Washington University in St. Louis, St. Louis, Missouri.
Kim-Anh DoDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
George F Vande WoudeLaboratory of Molecular Oncology, Van Andel Institute, Grand Rapids, Michigan.
John MendelsohnDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Naoto T UenoDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0166-7275
Gordon B MillsDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Debu TripathyDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. dtripathy@mdanderson.org sliu@mdanderson.org.
Ana M Gonzalez-AnguloDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
The University of Texas MD Anderson Cancer Center · USWashington University in St. Louis · USVan Andel Institute · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancerU01CA217842 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DENEEN, BENJAMIN, MILLS, GORDON B. · 2017 to 2021
$3.6M
NCI NIH HHS P30 CA016672NCI NIH HHS U01 CA217842
6 · The paper itself

Abstract

There is compelling evidence that oncogenic

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsBridged Bicyclo Compounds, HeterocyclicCell Line, TumorCell ProliferationCell SurvivalClass I Phosphatidylinositol 3-KinasesDrug Resistance, NeoplasmFemaleHepatocyte Growth FactorHumansIndazolesMutationPhosphorylationProto-Oncogene Proteins c-metPyrimidines1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidineBridged Bicyclo Compounds, HeterocyclicClass I Phosphatidylinositol 3-KinasesHepatocyte Growth FactorHGF protein, humanIndazolesMET protein, humanPIK3CA protein, humanProto-Oncogene Proteins c-metPyrimidinesSulfonamides

Identifiers

PMID30518672
PMCPMC7357548
OpenAlexW2913939071

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.